SOM3355 (bevantolol hydrochloride) ( DrugBank: Bevantolol )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
8ハンチントン病1

8. ハンチントン病


臨床試験数 : 242 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-003453-28-ES
(EUCTR)
28/03/202230/12/2021Phase IIb study assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington’s Disease with choreic movements.Phase IIb, randomized, double-blind, placebo-controlled study in parallel groups assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington’s Disease with choreic movements. Huntington’s Disease with choreic movements.
MedDRA version: 20.0;Level: LLT;Classification code 10020469;Term: Huntington's chorea;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Calvan (bevantolol hydrochloride)
Product Name: SOM3355 (bevantolol hydrochloride)
Product Code: SOM3355
INN or Proposed INN: BEVANTOLOL HYDROCHLORIDE
Trade Name: Calvan (bevantolol hydrochloride)
Product Name: SOM3355 (bevantolol hydrochloride)
Product Code: SOM3355
INN or Proposed INN: BEVANTOLOL HYDROCHLORIDE
SOM Innovation Biotech SA (SOM Biotech)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
129Phase 2France;Poland;Spain;Germany;United Kingdom;Switzerland;Italy